Drug news

Symbicort faces generic rival from Teva with CHMP recommendation for DuoResp Spiromax and BiResp Spiromax for Asthma and COPD - AstraZeneca

Read time: 1 mins

Last updated:22nd Feb 2014

Published:22nd Feb 2014

Source: Pharmawand

Teva Pharmaceutical Industries Ltd. has CHMP recommendation for a new generic version of Symbicort (budesonide plus formoterol) from AstraZeneca. The generic formulation will be marketed as DuoResp Spiromax and BiResp Spiromax, and is likely to be approved for the treatment of Asthma and Chronic Obstructive Pulmonary Disease.

Symbicort generated $3.48 billion in sales for AstraZeneca in 2013. Symbicort also faces competition from Breo Ellipta from GSK and generic versions of Glaxo�s Advair which are now being approved, specifically AirFlu Sal Fospira from Sandoz. The CHMP also recently recommended approval of Anoro Ellipta from GSK for the treatment of COPD, as another potential competitor to Symbicort.

Learning Zone Homepage

Respiratory Care

The Respiratory Care Learning Zone contains essential information on Inhaled Therapies in Asthma and COPD and its Management. The Learning Zone also has an Educational Resources section which features slide kits, congress news and webinars and videos relevant to asthma and COPD.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation for Tofidence (tocilizumab biosimilar)

Biogen Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Tofidence (tocilizumab), a biosimilar monoclonal antibody referencing Rocactemra

1 mins

Drug news

New data show Rinvoq (upadacitinib) demonstrated superiority versus Dupixent (dupilumab) across primary and all secondary endpoints in an open-label head-to-head atopic dermatitis study

AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase IIIb/IV study that evaluated the efficacy and safety of upadacitinib (Rinvoq, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (Dupixent, per its labeled dose) in adults and adolescents (greater than 12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable

2 min

Drug news

FDA approves Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections

Utility Therapeutics received approval from the FDA for Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus

1 min

See all news